TY - JOUR T1 - ADNC-RS, a clinical-genetic risk score, predicts Alzheimer’s pathology in autopsy-confirmed Parkinson’s Disease and Dementia with Lewy Bodies JF - medRxiv DO - 10.1101/2020.04.07.20056614 SP - 2020.04.07.20056614 AU - David L Dai AU - Thomas F Tropea AU - John L Robinson AU - Eunran Suh AU - Howard Hurtig AU - Daniel Weintraub AU - Vivianna Van Deerlin AU - Edward B. Lee AU - John Q Trojanowski AU - Alice S Chen-Plotkin Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/10/2020.04.07.20056614.abstract N2 - Growing evidence suggests overlap between Alzheimer’s disease (AD) and Parkinson’s disease (PD) pathophysiology in a subset of patients. Indeed, 50-80% of autopsy cases with a primary clinicopathological diagnosis of Lewy body disease (LBD) – most commonly manifesting during life as PD – have concomitant amyloid-beta and tau pathology, the defining pathologies of AD. Here we evaluated common genetic variants in genome-wide association with AD as predictors of concomitant AD pathology in the brains of people with a primary clinicopathological diagnosis of PD or Dementia with Lewy Bodies (DLB), diseases both characterized by neuronal Lewy bodies. 208 consecutive autopsy-confirmed cases of PD or DLB were assessed for AD neuropathological change (ADNC), and these same cases were genotyped at 20 single nucleotide polymorphisms (SNPs) found by genome-wide association study to associate with risk for AD. In a training set of the first 127 individuals, we developed a logistic regression model predicting the presence of ADNC, using backward stepwise regression for model selection and 10-fold cross-validation to estimate performance. We then assessed model performance in a separate test set of the next 81 individuals. The best-fit model generated a risk score for ADNC (ADNC-RS) based on age at disease onset and genotype at three SNPs (APOE, BIN1, and SORL1 loci). In the training set, the area under the receiver operating curve (AUC) for this model was 0.751. In the test set, the AUC was 0.781. Individuals with ADNC-RS in the top quintile had four-fold likelihood of having AD pathology at autopsy compared with those in each of the lowest two quintiles. In patients with autopsy-confirmed PD or DLB a simple model incorporating three AD-risk SNPs and age at disease onset substantially enriches for concomitant AD pathology at autopsy, with implications for identifying LBD patients in which targeting amyloid-beta or tau is a therapeutic strategy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the NIH (RO1 NS115139, P30 AG010124, U19 AG062418) and a Biomarkers Across Neurodegenerative Diseases (BAND) grant from the Michael J. Fox Foundation/Alzheimer’s Association/Weston Institute. Alice Chen-Plotkin is additionally supported by the Parker Family Chair.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon final publication, or by request. ER -